Febuxostat National Contract   3

Background
The Defense Logistics Agency (DLA), Directorate of Medical Materiel provides pharmaceutical products for the Department of Defense (DoD) to its customers through its Pharmaceutical Prime Vendor program. The Department of Veterans Affairs (VA) provides pharmaceutical products to its customers as well as the Indian Health Service (IHS) and the Bureau of Prisons (BoP) through the VA Pharmaceutical Prime Vendor Program. Hereafter these programs are collectively referred to as the “PPV.” A prime vendor is an independent business concern that functions as a purchaser's primary source for specified classes of products and is responsible for the delivery of goods. As a part of the Pharmaceutical Prime Vendor Program, this solicitation will establish a national contract for the items listed in the schedule. The PPV Programs consist of separate contracts which establish the fees for the distribution of pharmaceutical products that are distributed through the PPV Programs on Federal Government contracts. The awardee consents to allow VA and DLA prime vendors to distribute the listed products in the schedule.

Work Details
The specific products to be manufactured or delivered under the contract include Febuxostat 40 MG Tablets – 30 Count* and Febuxostat 80 MG Tablets – 30 Count*. The quantities specified in the Schedule are estimates only. The package size is unit of use and is subject to Statement of Work - “Preparation for Delivery” requirement.

Period of Performance
The contract performance date shall be 45 days (or sooner upon mutual agreement) after the date of contract award. This is the date the contractor shall be ready to fill orders from the PPV contractors.